Pharmacogenomic study for personalized medicine
Drug metabolizing enzymes and transporters
Cardiovascular pharmacology and neuropharmacology
Journal Articles
(2024)
Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism.
ARCHIVES OF PHARMACAL RESEARCH.
47,
2
(2024)
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.
ARCHIVES OF PHARMACAL RESEARCH.
47,
1
(2023)
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.
ARCHIVES OF PHARMACAL RESEARCH.
46,
11-12
(2023)
Adinazolam, a Benzodiazepine-Type New Psychoactive Substance, Has Abuse Potential and Induces Withdrawal Symptoms in Rodents.
ACS CHEMICAL NEUROSCIENCE.
14,
18
(2023)
Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone.
ARCHIVES OF PHARMACAL RESEARCH.
46,
8
(2023)
Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System.
ACS CHEMICAL NEUROSCIENCE.
14,
15
(2023)
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
ARCHIVES OF PHARMACAL RESEARCH.
46,
5
(2023)
Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects.
ARCHIVES OF PHARMACAL RESEARCH.
46,
2
(2022)
Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.
ARCHIVES OF PHARMACAL RESEARCH.
45,
8
(2022)
Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
ARCHIVES OF PHARMACAL RESEARCH.
45,
6
(2022)
Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.
ARCHIVES OF PHARMACAL RESEARCH.
45,
5
(2022)
Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.
ARCHIVES OF PHARMACAL RESEARCH.
45,
2
(2021)
Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.
ARCHIVES OF PHARMACAL RESEARCH.
44,
12
(2021)
Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients.
ARCHIVES OF PHARMACAL RESEARCH.
44,
12
(2021)
Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin to related CYP2D6*10 allele.
ARCHIVES OF PHARMACAL RESEARCH.
44,
11
(2021)
Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
ARCHIVES OF PHARMACAL RESEARCH.
44,
7
(2020)
Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
ARCHIVES OF PHARMACAL RESEARCH.
43,
12
(2020)
ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan.
ARCHIVES OF PHARMACAL RESEARCH.
43,
11
(2020)
Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.
ARCHIVES OF PHARMACAL RESEARCH.
43,
11
(2020)
Flavonoids as therapeutic candidates for emotional disorders such as anxiety and depression.
ARCHIVES OF PHARMACAL RESEARCH.
43,
11
Publications
(2018)
약물학.
범문에듀케이션.
Lead author
(2016)
약국실무.
신일상사.
Co-author
(2016)
약물학 정리와 시험.
신일북스.
Co-author
(2015)
약물작용 기본이론.
군자촐판.
Lead author
(2015)
약물.
범문에듀케이.
Lead author
(2014)
약물치료학요약집.
신일북.
Co-author
(2014)
약국실무요점.
신일북스.
Co-author
(2014)
기초약무실습.
신일북.
Co-author
(2014)
약물치료학.
신일북.
Co-author
(2013)
약물작용 기초이론.
군자출판사.
Lead author
(2013)
임상약리와 약물치료.
신일북스.
Lead author
(2012)
기초약무실습.
신일북스.
Co-author
(2012)
약리학 정리와 시험.
신일북스.
Co-author
(2012)
약물학.
신일북스.
Co-author
(2012)
약학입문.
신일북스.
Lead author
(2011)
약물상호작용.
신일상사.
Lead author
(2009)
약물치료학.
신일상사.
Lead author
(2009)
약물학.
신일북스.
Lead author
(2008)
하버드 핵심약리학.
이퍼블릭.
Co-author
(2007)
약제별복약지도.
약사공론.
Co-author
Patent/Intellectual Property
CYP2C9유전자의 유전형을 이용한 멜록시캄의 약물반응 예측방법.
10-2012-0097359.
20141106.
KOREA, REPUBLIC OF
CYP2C9유전자의 유전형을 이용한 자피루카스트의 약물반응 예측방법.
10-2012-0097360.
20140709.
KOREA, REPUBLIC OF
베르베린을 유효성분으로 함유하는 모르핀류 중독, 또는 진통 내성 형성 예방, 억제용 약재.
200380102287.9.
20100505.
CHINA
베르베린을 유효성분으로 함유하는 모르핀류 중독, 또는 진통 내성 형성 예방, 억제용 약재.
2005-501862.
20100430.
JAPAN
약물의존종독을 예방 및 치료하기 위한 바닐로이드 수용체 길항제.
00000000.
20070912.
KOREA, REPUBLIC OF
Pharmacological composition containing berberine as effective ingredient for preventing and treating addiction or tolerance to morphine.
US 7,250,422 B2.
20070731.
UNITED STATES
Apicidin-derovatives, their synthetic methods, and antitumor compositions containing the same.
US6831061 B2.
20041214.
UNITED STATES
애피시딘 유도체, 이의 합성방법 및 이를 포함하는 항암제조성물.
0456047.
20041028.
KOREA, REPUBLIC OF
Conference Paper
(2021)
Development of physiologically based pharmacokinetic (PBPK) model for meloxicam related to CYP2C9 genetic polymorphism.
2021 대한약학회 추계학술대회.
KOREA, REPUBLIC OF
(2021)
Physiologically based pharmacokinetic (PBPK) modeling and simulation for risperidone and its active metabolite related to CYP2D6 genetic polymorphism.
2021 대한약학회 추계학술대회.
KOREA, REPUBLIC OF
(2021)
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide in different CYP2C9 and CYP2C19 genotypes.
2021 대한약학회 추계학술대회.
KOREA, REPUBLIC OF
(2021)
Physiologically based pharmacokinetic (PBPK) modeling of tamsulosin related to CYP2D6*10 allele.
2021 대한약학회 추계학술대회.
KOREA, REPUBLIC OF
(2021)
Physiologically based pharmacokinetic modeling of omeprazole, proton pump inhibitor, considering CYP2C19 genetic polymorphism in humans.
2021 대한약학회 추계학술대회.
KOREA, REPUBLIC OF
(2021)
Simulation of candesartan physiologically based pharmacokinetic model according to CYP2C9 genetic polymorphism.
대한약학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
CORRELATION PREDICTION BETWEEN PROPRANOLOL PHARMACOKINETICS AND CYP2D6 GENETIC POLYMORPHISM USING PBPK MODEL.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
DEVELOPMENT OF VORICONAZOLE PBPK MODEL BASED ON CYP2C19 GENETIC POLYMORPHISM USING IN VITRO METABOLISM.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
Effect of CYP2D6 genetic polymorphism on metoclopramide in adults and children: using physiologically based pharmacokinetic modeling.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
PBPK MODELING OF THE EFFECT OF CYP2D6 ENZYME GENETIC POLYMORPHISM ON THE PHARMACOKINETICS OF OPIOID DRUG.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING: EFFECT OF CYP2C9 GENETIC POLYMORPHISM ON CANDESARTAN IN PEDIATRIC.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
PREDICTION OF CYP2C9 GENETIC POLYMORPHISM OF FLURBIPROFEN USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
SIMULATION OF RISPERIDONE AND ITS METABOLITE, PALIPERIDONE PARMACOKINETIC MODEL ACCORDING TO CYP2D6 GENOTYPES.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
THE PHARMACOKINETICS PREDICTION OF TAMSULOSIN ASSOCIATED WITH CYP2D6 GENETIC FACTOR USING PBPK MODEL.
대한약리학회 추계학술대회.
KOREA, REPUBLIC OF
(2020)
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation of Lornoxicam to Develop Personalized Drug Optimization regarding to CYP2C9 Genetic Polymorphism.
Experimental Biology 2020.
UNITED STATES
(2020)
Physiologically Based Pharmacokinetic Modeling of Propranolol in Relation to CYP2D6 Genotypes.
Experimental Biology 2020.
UNITED STATES
(2020)
Prediction of Flurbiprofen Pharmacokinetics by CYP2C9 Genotypes in Populations Utilizing a Physiological Based Pharmacokinetic Modeling.
Experimental Biology 2020.
UNITED STATES
(2019)
AG-OX, a potent inhibitor of interactions between S100A9 and RAGE/TLR4, selectively inhibits S100A9-positive triple-negative breast cancer.
ASCEPT_PAGANZ 2019 Joint Scientific Meeting.
NEW ZEALAND
(2019)
Estimating concentration of venlafaxine and its metabolite in case of enzyme polymorphism and renal impairment.
ASCEPT_PAGANZ 2019 Joint Scientific Meeting.
NEW ZEALAND
(2019)
Prediction of flurbiprofen pharmacokinetics from using in vitro metabolism data in relation to CYP2C9 genetic polymorphism..
ASCEPT_PAGANZ 2019 Joint Scientific Meeting.
NEW ZEALAND